Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22555679 | 1.00 | OPRK1 (0.36) | OPRK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30514796 | 1.00 | OPRK1 (0.36) | OPRK1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL21187254 | 0.86 | SIGMAR1 (0.33) | ALDH1A1SIGMAR1HTR2A | |
| SCHEMBL21176973 | 0.79 | MEN1 (0.33) | HDAC6LMNASMN1; SMN2ALOX5MEN1 | |
| SCHEMBL29452911 | 0.79 | MEN1 (0.33) | HDAC6LMNASMN1; SMN2ALOX5MEN1 | |
| SCHEMBL30514798 | 0.79 | MEN1 (0.33) | HDAC6LMNASMN1; SMN2ALOX5MEN1 | |
| SCHEMBL21177130 | 0.79 | MEN1 (0.33) | HDAC6LMNASMN1; SMN2ALOX5MEN1 | |
| SCHEMBL29452980 | 0.77 | BCHE (0.40) | LMNASMN1; SMN2ALOX5SIGMAR1 | |
| SCHEMBL21177006 | 0.77 | BCHE (0.40) | LMNASMN1; SMN2ALOX5SIGMAR1 | |
| SCHEMBL21176974 | 0.76 | GPR84 (0.34) | OPRK1HDAC8ALOX5GPR84HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | claimed |
| US-12545653-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | USA Elixiria Biotech Inc. | 2023-07-04 | — | — | US | disclosed |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | disclosed |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. | 2020-10-22 | — | — | US | disclosed |
| WO-2019141229-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | 上海怡立舍生物技术有限公司 | 2019-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545653-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARD, PPARG | OPRK1 498/4885HDAC3 406/4885HDAC4 974/4885 |
| US-11691953-B2 | Compound as PPAR agonist and application thereof | PPARA, PPARG, PPARD | OPRK1 719/4885HDAC3 592/4885HDAC4 1144/4885 |
| US-20200331868-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | OPRK1 719/4885HDAC3 592/4885HDAC4 1144/4885 |
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | OPRK1 719/4885HDAC3 592/4885HDAC4 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.